Држава: Сједињене Америчке Државе
Језик: Енглески
Извор: NLM (National Library of Medicine)
EXEMESTANE (UNII: NY22HMQ4BX) (EXEMESTANE - UNII:NY22HMQ4BX)
Mylan Pharmaceuticals Inc.
EXEMESTANE
EXEMESTANE 25 mg
ORAL
PRESCRIPTION DRUG
Exemestane tablets are indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to exemestane tablets for completion of a total of five consecutive years of adjuvant hormonal therapy [see Clinical Studies (14.1)] . Exemestane tablets are indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy [see Clinical Studies (14.2)]. Exemestane tablets are contraindicated in patients with a known hypersensitivity to the drug or to any of the excipients. Based on findings in animal studies and its mechanism of action, exemestane tablets can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1)] . Limited human data from case reports are insufficient to inform a drug-associated risk. In animal reproduction studies, administration of exemestane to pregnant rats and rabbits caused increased inc
Exemestane Tablets are available containing 25 mg of exemestane, USP. The 25 mg tablets are white, film-coated, round, unscored tablets debossed with X on one side of the tablet and M on the other side. They are available as follows: NDC 0378-5001-93 bottles of 30 tablets Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.
Abbreviated New Drug Application
EXEMESTANE- EXEMESTANE TABLET, FILM COATED MYLAN PHARMACEUTICALS INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE EXEMESTANE TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR EXEMESTANE TABLETS. EXEMESTANE TABLETS, FOR ORAL USE INITIAL U.S. APPROVAL: 1999 INDICATIONS AND USAGE Exemestane tablets are an aromatase inhibitor indicated for: • • DOSAGE AND ADMINISTRATION Recommended Dose: One 25 mg tablet once daily after a meal (2.1). DOSAGE FORMS AND STRENGTHS Tablets: 25 mg (3) CONTRAINDICATIONS • WARNINGS AND PRECAUTIONS • • • ADVERSE REACTIONS • • TO REPORT SUSPECTED ADVERSE REACTIONS, CONTACT MYLAN AT 1-877-446-3679 (1-877-4-INFO-RX) OR FDA AT 1-800-FDA-1088 OR WWW.FDA.GOV/MEDWATCH. DRUG INTERACTIONS • USE IN SPECIFIC POPULATIONS • SEE 17 FOR PATIENT COUNSELING INFORMATION AND FDA-APPROVED PATIENT LABELING. REVISED: 6/2018 adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to exemestane tablets for completion of a total of five consecutive years of adjuvant hormonal therapy (14.1). treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy (14.2). Patients with a known hypersensitivity to the drug or to any of the excipients (4). Reductions in bone mineral density (BMD) over time are seen with exemestane use (5.1). Routine assessment of 25-hydroxy vitamin D levels prior to the start of aromatase inhibitor treatment should be performed (5.2). Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception (5.6, 8.1, 8.3). Early breast cancer: Adverse reactions occurring in ≥ 10% of patients in any treatment group (exemestane tablets vs. tamoxifen) were hot flushes (21.2% vs. 19.9%), fatigue (16.1% vs. 14.7%), arthralgia (14.6% vs. 8.6%), headache (1 Прочитајте комплетан документ